Fisetin to slow worsening of sepsis in older hospital patients
Part of Infections clinical trials.
This Phase 2 trial tests whether a drug called fisetin can slow the progression of sepsis once you are admitted to the hospital. It may help patients recover more quickly or avoid worsening, but eligibility depends on how severe the illness is and what other treatments you need.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 65 or older
- You are hospitalized for a new acute infection that your care team believes is the main problem
- Your sepsis severity score (SOFA) is greater than 1
- You were admitted to the hospital (not just seen in an outpatient setting) and are expected to stay at least 48 hours
- You are not admitted to the ICU for this hospital stay
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether fenofibrate (a cholesterol medicine) or silymarin (an herbal extract) can help adults with sepsis recover. You may need to be in the hospital with an active infection to participate.
This study tests whether a medicine called dapagliflozin can help reduce inflammation in people with sepsis (a serious blood infection that can cause organ failure). It focuses on a protein in the blood that controls inflammation and might improve recovery.
This trial tests whether a type of diabetes medicine (SGLT2 inhibitors) can help adults with sepsis, a life-threatening response to infection. If you have new-onset sepsis and can take oral medicine, you may be eligible.
This trial tests whether a quick genetic test can help doctors choose the right treatment for patients with a suspected severe infection (sepsis) more quickly. The goal is to improve recovery by personalizing care based on your body's response.
This trial tests a new treatment to protect and repair the layer of cells lining your blood vessels (glycocalyx) during sepsis. It aims to improve recovery from severe infections.
This study tests whether giving an early antibiotic (meropenem) based on a new blood test (PSP) can prevent serious infections (sepsis) in people who come to the emergency department with signs of infection. The goal is to find out if this approach helps them get better faster and avoid more severe illness.
Hear when a new Sepsis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.